| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-01-23 | Herantis Pharma (Finland) Renishaw (UK) | CDNF - recombinant human cerebral dopamine neurotrophic factor | Parkinson's disease | clinical research |
Neurological diseases - CNS diseases | Clinical research agreement |
| 2017-01-23 | Domain Therapeutics (France) Merck KGaA (Germany) | adenosine receptor antagonist drugs for use in combination with immune checkpoint inhibitors | licensing commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2017-01-23 | Cellectis (France) | member of the clinical advisory board | nomination | Cancer - Oncology | Nomination | |
| 2017-01-23 | Kymab (UK) | nomination | Nomination | |||
| 2017-01-23 | Incyte (USA - DE) Merus (The Netherlands) | bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform | R&D - research - development - licensing | Cancer - Oncology | Research agreement | |
| 2017-01-20 | BMS (USA - NY) Merck&Co (USA - NJ) Ono Pharmaceutical (Japan) | Keytruda® (pembrolizumab - MK-3475) | Cancer - Oncology | Licensing agreement | ||
| 2017-01-19 | Armagen (USA - CA) | nomination |
Neurological diseases - CNS diseases | Nomination | ||
| 2017-01-19 | Adocia (France) | restructuring | Metabolic diseases | Restructuring | ||
| 2017-01-19 | Genenta Science (Italy) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2017-01-18 | Takeda Pharmaceutical (Japan) Ovid Therapeutics (USA - NY) | TAK-935 | rare pediatric epilepsies | clinical research commercialisation |
Rare diseases - CNS diseases - Neurological diseases | Clinical research agreement |
| 2017-01-18 | Minoryx Therapeutics (Spain) | scientific advisory board | nomination | Rare diseases | Nomination | |
| 2017-01-18 | Servier (France) MaSTherCell (Belgium) | manufacturing platform for allogeneic cell therapies | services contract manufacturing
|
Technology - Services | Services contract | |
| 2017-01-17 | Bavarian Nordic (Denmark) | chief operating officer | nomination | Cancer - Oncology - Infectious diseases | Nomination | |
| 2017-01-17 | Galapagos (Belgium) | chief medical officer | nomination | Nomination | ||
| 2017-01-17 | Merck KGaA (Germany) | new facility in Mollet des Vallès (Spain) | opening of new premises |
Opening of new premises | ||
| 2017-01-17 | Agenus (USA - MA) Merck&Co (USA - NY) National Cancer Institute (USA) | Prophage™ (HSPPC-96) and pembrolizumab (Keytruda®) | newly diagnosed glioblastoma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2017-01-17 | Bavarian Nordic (Denmark) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2017-01-16 | Leon-nanodrugs (Germany) Bionpharma (USA - NJ) | MicroJet Reactor (MJR®) based dermatological product | development |
Dermatological diseases | Development agreement | |
| 2017-01-16 | Oryzon Genomics (Spain) | scientific advisory board | nomination | Neurodegenerative diseases - Neuroinflammatory diseases | Nomination | |
| 2017-01-13 | Eli Lilly (USA - IN) Merck&Co (USA - NJ) | Lartruvo™ (olaratumab) and Keytruda® (pembrolizumab) | soft tissue sarcoma | clinical research |
Cancer - Oncology | Clinical research agreement |
